Enzymatica’s growth strategy has three pillars: strengthening the company’s position in existing markets, expanding into more geographic markets and developing more unique products. In 2020 ColdZyme® strengthened its position on the Swedish market by capturing market share. Enzymatica signed new distributor agreements with leading international pharmaceutical companies and we now have agreements for ColdZyme in about 60 markets. Finally, we continued our work on line extensions, or new product variants, of ColdZyme, as well as on developing future products based on barrier technology.
